By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Intarcia


Drug Discovery

Company News
Intarcia Touts Large Phase III Trial Diabetes Data, Bags $75 Million 5/6/2016 10:19:38 AM
Intarcia Appoints Anthony Hurley As VP, Global Commercial Manufacturing and Operations, Reporting To Chairman & CEO Kurt Graves 4/5/2016 7:28:07 AM
Intarcia Appoints Dr. John Yee Into New Role Of VP, Global Medical Affairs, Safety And Operations, Reporting Directly To Chairman & CEO Kurt Graves 2/8/2016 10:45:00 AM
Intarcia Announces Upcoming Presentation At 34th Annual J.P. Morgan Healthcare Conference 1/7/2016 11:39:00 AM
Intarcia CEO Kurt Graves Discusses Phoundry Acquisition and Future of Diabetes Treatment 9/30/2015 12:47:09 PM
Intarcia Buys One Month Old Startup Phoundry 9/24/2015 11:26:27 AM
Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD 9/16/2015 10:31:43 AM
Intarcia Announces New Top-Line Phase III Results For Investigational Therapy ITCA 650 In Type 2 Diabetes 8/19/2015 8:14:26 AM
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/19/2015 6:38:22 AM
Intarcia Announces Presentations At American Diabetes Association Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes 6/8/2015 10:06:37 AM